European stocks turn higher amid stalled U.S.-Iran negotiations, earnings deluge

European equities rose 0.2% on Tuesday as markets weighed stalled Iran peace talks against a raft of earnings updates. Brent crude climbed again as the Strait of Hormuz remained largely shut, keeping oil well above pre-war levels and reinforcing inflation and central bank concerns. BP rose after first-quarter profit more than doubled, Norwegian Air Shuttle gained on a smaller-than-expected operating loss, while Novartis fell after core operating profit missed expectations.

Analysis

The market is still underpricing the second-order inflation impulse from a sustained Hormuz disruption: the first move is obvious energy beta, but the bigger squeeze is on sectors with unhedged fuel cost pass-through and weak pricing power. That argues for a relative-value read-through favoring upstream energy and selective shippers/transport hedgers, while airlines, chemicals, and European cyclicals with thin operating margins face a multi-quarter earnings compression if crude remains elevated.

The key nuance is that this is no longer a pure commodity story; it is a macro-volatility regime shift. Higher breakevens and headline inflation increase the probability that rate-cut expectations get pushed out, which is negative for long-duration equities and especially for balance-sheet-sensitive healthcare names that are being sold on even modest earnings misses. Novartis looks less like a single-company stumble and more like the kind of defensiveness investors are unwilling to pay up for when inflation and policy uncertainty rise simultaneously.

Consensus appears too anchored to a short geopolitical flare-up. If shipping remains impaired for weeks rather than days, energy-driven margin pressure will show up first in travel and industrial input costs, then in broader Euro earnings revisions; if instead there is any credible diplomatic channel reopening the waterway, the tape could unwind violently because positioning is already crowded in the inflation hedge trade. The highest-probability setup is not directional index longs, but dispersion: long cash-generative energy, short rate-sensitive defensives and fuel-exposed transport.

The contrarian angle on Novartis is that the miss may be an entry point only if the broader market concludes this is idiosyncratic rather than the start of multiple compression across European pharma. If inflation expectations keep drifting higher, even defensive growth loses its premium, so the stock may struggle to re-rate until bond yields stabilize and earnings visibility improves.

Key Decisions for Investors

• Go long XLE vs short XLV for 2-6 weeks: energy retains direct earnings leverage to sustained oil strength, while healthcare multiple support erodes if inflation/rates stay sticky; target 5-8% relative outperformance, stop if Brent falls back below pre-spike range or rates rally sharply.
• Buy BP/CVX call spreads dated 1-3 months out: prefer defined-risk upside participation because the market is still modeling too conservative a duration for elevated crude; exit on any credible Hormuz de-escalation headline.
• Short airline exposure via EU travel baskets or carrier names for 1-2 months: fuel hedges soften the first hit, but the second-order hit is demand and margin compression once ticket pricing lags input costs; risk/reward improves if oil remains elevated for several weeks.
• Avoid or underweight long-duration defensives with earnings sensitivity, including NVS, until the market has repriced inflation expectations: use rallies to reduce exposure, since the miss may not be fully company-specific if macro uncertainty persists.
• Pair long upstream energy vs short European industrial cyclicals over 1-2 quarters: if shipping disruptions persist, input costs and delivery uncertainty should pressure cyclical revisions before the market fully reflects the earnings downside.